Pierre Laneuville
Overview
Explore the profile of Pierre Laneuville including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
304
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Busque L, Beaudet M, Harnois M, Moussa H, Szuber N, Mollica L, et al.
Blood Cancer J
. 2025 Mar;
15(1):35.
PMID: 40069191
No abstract available.
2.
Pandey A, Roos K, Jiang Y, Mangoff K, Klein G, Forward N, et al.
EJHaem
. 2025 Jan;
6(1):e1062.
PMID: 39866944
Introduction: Patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have an unmet medical need. The objective of this trial was to assess the efficacy and toxicities of a novel...
3.
Roussel L, Bernier S, Perez A, Sun Y, Angers I, Laneuville P, et al.
Br J Haematol
. 2024 Oct;
205(5):2089-2093.
PMID: 39364635
No abstract available.
4.
Schweitzer L, Barkati S, Laneuville P, Fox S, Vinh D
J Clin Immunol
. 2024 Apr;
44(4):97.
PMID: 38587706
No abstract available.
5.
Perusini M, Novitzky-Basso I, Atenafu E, Forrest D, Bence-Bruckler I, Savoie L, et al.
Br J Haematol
. 2023 Sep;
203(5):781-791.
PMID: 37697469
Multiple studies have reported a significant treatment-free remission (TFR) rate of 50%-60% in patients with chronic myeloid leukaemia (CML) who discontinue tyrosine kinase inhibitor (TKI) therapy. However, the remaining half...
6.
Amitai I, Roos K, Rashedi I, Jiang Y, Mangoff K, Klein G, et al.
Eur J Haematol
. 2023 May;
111(2):191-200.
PMID: 37157906
Background: Patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have limited treatment options. Methods: R/R DLBCL patients, who were mostly ineligible for ASCT due to age or comorbidities, were...
7.
Kim D, Kim T, Atenafu E, Novitzky Basso I, Forrest D, Bence-Bruckler I, et al.
Br J Haematol
. 2021 Sep;
196(1):136-145.
PMID: 34496035
The doubling time (DT) of the BCR-ABL1 quantitative polymerase chain reaction (qPCR) transcript level reflects the re-growing fraction of leukaemic cells after discontinuation of tyrosine kinase inhibitor (TKI). The present...
8.
Kim D, Novitzky-Basso I, Kim T, Atenafu E, Forrest D, Savoie L, et al.
Br J Haematol
. 2021 Apr;
193(4):779-791.
PMID: 33876423
Although total duration of tyrosine kinase inhibitor (TKI) therapy and of molecular response at 4 log reduction or deeper (MR4) correlates with treatment-free remission (TFR) success after TKI discontinuation, the...
9.
Simpson-Poirier K, Harnois M, Olney H, Sirhan S, Gratton M, Assouline S, et al.
Am J Hematol
. 2021 Mar;
96(6):E200-E203.
PMID: 33719144
No abstract available.
10.
Klil-Drori A, Yin H, Azoulay L, Del Corpo A, Harnois M, Gratton M, et al.
Cancer
. 2018 Nov;
125(4):618-625.
PMID: 30423211
Background: In the current study, the authors determined whether adhering to molecular monitoring guidelines in patients with chronic myeloid leukemia (CML) is associated with major molecular response (MMR) and assessed...